1600511-63-4 Usage
Chemical structure
1-(5-bromo-2,3-difluorophenyl)ethanone is a chemical compound that contains a keto group and a substituted phenyl ring.
Applications
It is commonly used as an intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other specialty chemicals.
Usage
It is also utilized in the production of fragrances and flavoring agents.
Unique properties
The presence of the bromine and difluorophenyl group in its structure gives it unique chemical and physical properties.
Research and industrial applications
It is useful in a variety of research and industrial applications due to its unique properties.
Regulation
Its synthesis and use are carefully regulated due to its potential impact on health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 1600511-63-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,0,0,5,1 and 1 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1600511-63:
(9*1)+(8*6)+(7*0)+(6*0)+(5*5)+(4*1)+(3*1)+(2*6)+(1*3)=104
104 % 10 = 4
So 1600511-63-4 is a valid CAS Registry Number.
1600511-63-4Relevant articles and documents
AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE
-
Page/Page column, (2014/05/07)
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.
